Hennion & Walsh Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Hennion & Walsh Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-14,942	Closed	-$1.09M	–	915
2024 Q3	$1.09M	Sell	14,942 -1,569	-10%	-$118K	0.05%	432
2024 Q2	$1.13M	Sell	16,511 -140	-0.8%	-$9.71K	0.06%	395
2024 Q1	$1.15M	Buy	16,651 +2,090	+14%	+$144K	0.06%	389
2023 Q4	$1.04M	Sell	14,561 -203	-1%	-$11.7K	0.06%	395
2023 Q3	$769K	Buy	14,764 +1,066	+8%	+$62.1K	0.05%	418
2023 Q2	$867K	Buy	13,698 +270	+2%	+$16.8K	0.05%	399
2023 Q1	$727K	Buy	13,428 +2,280	+20%	+$110K	0.04%	428
2022 Q4	$590K	Buy	+11,148	New	+$559K	0.04%	463

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Hennion & Walsh Asset Management's ITCI Position: Q4 2024 in Review

Hennion & Walsh Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2024, closing a stake of 14,942 shares — an estimated $1.09M sold.

Hennion & Walsh Asset Management first reported a position in ITCI in Q4 2022 and held it in 8 quarters. The position peaked at $1.15M in Q1 2024. 387 funds tracked by Wall St. Rank hold ITCI as of Q4 2024.

Hennion & Walsh Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2024 after selling out during the quarter.
Hennion & Walsh Asset Management sold 14,942 Intra-Cellular Therapies Inc. shares in Q4 2024, an estimated $1.09M.
Hennion & Walsh Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2022 and held it in 8 quarters.
Hennion & Walsh Asset Management's Intra-Cellular Therapies Inc. position peaked at $1.15M in Q1 2024.
387 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2024.

Based on Hennion & Walsh Asset Management's 13F filing for Q4 2024, filed 15 Jan 2025.